James Kalabus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James Kalabus has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anthony W. Tolcher
NEXT Oncology, San Antonio, Texas
43 shared publications - Brianne O’NEill
Inhibrx Biosciences, Inc. 15 , La Jolla, California
43 shared publications - David Berz
Valkyrie Clinical Trials, Los Angeles, California
43 shared publications - Lane Senne
Inhibrx Biosciences, Inc. 15 , La Jolla, California
43 shared publications - Alexander I. Spira
Virginia Cancer Specialists Research Institute, Fairfax, VA
31 shared publications - D. Ross Camidge
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S3 summarizes the treatment-emergent adverse events
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S3 summarizes the treatment-emergent adverse events
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S2 shows patient disposition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S2 shows patient disposition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S5 is a schematic of the study design
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S5 is a schematic of the study design
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S4 shows that addition of an orthogonal anti–PD-1 antibody to INBRX-105-a resulted in enhanced antitumor activity in mouse tumor models and improved blockade of PD-1/PD-L1 interactions compared with INBRX-105-a alone
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S4 shows that addition of an orthogonal anti–PD-1 antibody to INBRX-105-a resulted in enhanced antitumor activity in mouse tumor models and improved blockade of PD-1/PD-L1 interactions compared with INBRX-105-a alone
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S2 shows that in vitro INBRX-105 resulted in greater T-cell modulation than a constitutive 4-1BB agonist that was provided alone or in combination with a PD-L1 antagonist
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S2 shows that in vitro INBRX-105 resulted in greater T-cell modulation than a constitutive 4-1BB agonist that was provided alone or in combination with a PD-L1 antagonist
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S1 summarizes the representativeness of study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S1 summarizes the representativeness of study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S7 summarizes the characteristics of patients who were responders to study treatment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S7 summarizes the characteristics of patients who were responders to study treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S3 shows that INBRX-105-a, a murine INBRX-105 surrogate, demonstrated potent antitumor activity, including T-cell tumor infiltration and induction of T-cell memory, in PD-L1+ mouse tumor models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S3 shows that INBRX-105-a, a murine INBRX-105 surrogate, demonstrated potent antitumor activity, including T-cell tumor infiltration and induction of T-cell memory, in PD-L1+ mouse tumor models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S4 summarizes the INBRX-105–related hepatic treatment-emergent adverse events
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S4 summarizes the INBRX-105–related hepatic treatment-emergent adverse events
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S5 summarizes the treatment-emergent adverse events that resulted in death
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S5 summarizes the treatment-emergent adverse events that resulted in death